Paul Fields

1.4k total citations
18 papers, 636 citations indexed

About

Paul Fields is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Paul Fields has authored 18 papers receiving a total of 636 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 10 papers in Oncology and 6 papers in Neurology. Recurrent topics in Paul Fields's work include Lymphoma Diagnosis and Treatment (12 papers), CNS Lymphoma Diagnosis and Treatment (6 papers) and Viral-associated cancers and disorders (5 papers). Paul Fields is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), CNS Lymphoma Diagnosis and Treatment (6 papers) and Viral-associated cancers and disorders (5 papers). Paul Fields collaborates with scholars based in United Kingdom, United States and India. Paul Fields's co-authors include N. George Mikhaeel, A.R. Timothy, Martin Hutchings, T. Nunan, Mufaddal Moonim, George Santis, Ronan Breen, Andrew Davies, Tobias Menne and Graham P. Collins and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Paul Fields

18 papers receiving 627 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Fields United Kingdom 11 462 203 203 172 144 18 636
T. Al Saati France 13 421 0.9× 65 0.3× 289 1.4× 47 0.3× 67 0.5× 21 596
Mayer Zaharia Peru 11 222 0.5× 110 0.5× 281 1.4× 25 0.1× 34 0.2× 18 480
Alexandra Stefanovic United States 11 350 0.8× 44 0.2× 268 1.3× 19 0.1× 220 1.5× 22 479
V. Romagosa Spain 14 334 0.7× 99 0.5× 175 0.9× 11 0.1× 64 0.4× 25 552
R E Hutchison United States 9 468 1.0× 82 0.4× 244 1.2× 16 0.1× 144 1.0× 14 598
Ren‐Ching Wang Taiwan 12 154 0.3× 77 0.4× 157 0.8× 15 0.1× 36 0.3× 53 481
Fabien Le Bras France 13 127 0.3× 29 0.1× 164 0.8× 41 0.2× 45 0.3× 41 519
JM Vose United States 11 206 0.4× 45 0.2× 244 1.2× 36 0.2× 53 0.4× 17 528
Douglas W. Kingma United States 8 372 0.8× 47 0.2× 261 1.3× 9 0.1× 84 0.6× 10 551
Ryan Jacobs United States 12 190 0.4× 42 0.2× 176 0.9× 121 0.7× 21 0.1× 59 505

Countries citing papers authored by Paul Fields

Since Specialization
Citations

This map shows the geographic impact of Paul Fields's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Fields with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Fields more than expected).

Fields of papers citing papers by Paul Fields

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Fields. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Fields. The network helps show where Paul Fields may publish in the future.

Co-authorship network of co-authors of Paul Fields

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Fields. A scholar is included among the top collaborators of Paul Fields based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Fields. Paul Fields is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Hamadani, Mehdi, Graham P. Collins, Paolo F. Caimi, et al.. (2021). Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. The Lancet Haematology. 8(6). e433–e445. 63 indexed citations
3.
4.
Collins, Graham P., Steven M. Horwitz, Mehdi Hamadani, et al.. (2019). ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT‐301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL). Hematological Oncology. 37(S2). 95–97. 8 indexed citations
5.
6.
7.
Gibb, Adam, Sarah Pirrie, Kim Linton, et al.. (2017). RESULTS OF a PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY). Hematological Oncology. 35(S2). 80–81. 10 indexed citations
8.
9.
Moonim, Mufaddal, Ronan Breen, Paul Fields, & George Santis. (2013). Diagnosis and Subtyping of De Novo and Relapsed Mediastinal Lymphomas by Endobronchial Ultrasound Needle Aspiration. American Journal of Respiratory and Critical Care Medicine. 188(10). 1216–1223. 66 indexed citations
10.
Coutinho, Rita, Alessia Dalla Pria, Katharine Bailey, et al.. (2013). HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. AIDS. 28(5). 689–697. 45 indexed citations
11.
Benton, Emma, Siobhan Crichton, R. Talpur, et al.. (2013). A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. European Journal of Cancer. 49(13). 2859–2868. 98 indexed citations
12.
13.
Hodson, Andrew, Daniel J. Laydon, Barbara J. Bain, Paul Fields, & Graham P. Taylor. (2012). Pre-morbid human T-lymphotropic virus type I proviral load, rather than percentage of abnormal lymphocytes, is associated with an increased risk of aggressive adult T-cell leukemia/lymphoma. Haematologica. 98(3). 385–388. 19 indexed citations
14.
Okosun, Jessica, Victoria Warbey, Kate Shaw, et al.. (2012). Interim fluoro-2-deoxy-D-glucose–PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection. AIDS. 26(7). 861–865. 13 indexed citations
15.
Benton, Emma, Siobhan Crichton, Nicholas Agar, et al.. (2010). Cutaneous Lymphoma International Prognostic Index (CLIPI). Research Portal (King's College London). 163. 11–11. 2 indexed citations
16.
Fields, Paul, et al.. (2008). Anaplastic lymphoma of the cervical esophagus presenting as a tracheoesophageal fistula. Head & Neck. 30(9). 1264–1268. 10 indexed citations
17.
Simpson, S. A., Graham P. Taylor, Estella Matutes, et al.. (2006). Combination Chemotherapy with CHOP-Daclizumab in HTLV-I Associated Adult T-Cell Leukaemia/Lymphoma.. Blood. 108(11). 2750–2750. 1 indexed citations
18.
Hutchings, Martin, N. George Mikhaeel, Paul Fields, T. Nunan, & A.R. Timothy. (2005). Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Annals of Oncology. 16(7). 1160–1168. 245 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T. Al Saati Breakdown of academic impact, for papers by Mayer Zaharia Breakdown of academic impact, for papers by Alexandra Stefanovic Breakdown of academic impact, for papers by V. Romagosa Breakdown of academic impact, for papers by R E Hutchison Breakdown of academic impact, for papers by Ren‐Ching Wang Breakdown of academic impact, for papers by Fabien Le Bras Breakdown of academic impact, for papers by JM Vose Breakdown of academic impact, for papers by Douglas W. Kingma Breakdown of academic impact, for papers by Ryan Jacobs
Rankless by CCL
2026